Table 1.
Treatment‐emergent adverse events (TEAEs) reported by more than one subject at any single dose
| System organ class adverse event | Pooled placebo n = 8 | GLPG0974 | |||
|---|---|---|---|---|---|
| 10 mg n = 6 | 30 mg n = 6 | 90 mg n = 6 | 250 mg n = 6 | ||
| Any AE | 1 | 1 | 1 | 2 | 0 |
| Gastrointestinal disorders | 0 | 0 | 0 | 1 | 0 |
| • Nausea | 0 | 0 | 0 | 1 | 0 |
| Infections and infestations | 1 | 0 | 0 | 0 | 0 |
| Urethritis chlamydial | 1 | 0 | 0 | 0 | 0 |
| Renal and urinary disorders | 0 | 0 | 0 | 1 | 0 |
| • Polyuria | 0 | 0 | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | 0 | 1 | 1 | 1 | 0 |
| • Cough | 0 | 0 | 0 | 1 | 0 |
| • Oropharyngeal pain | 0 | 1 | 1 | 0 | 0 |
n = number of subjects with that observation.